Aspartic Acid Proteases as Therapeutic Targets

Ghosh, Arun K.


Table of Contents

List of Contributors.

Preface.

A Personal Foreword.

Part One. Overview of Aspartic Acid Proteases.

1. Introduction to the Aspartic Proteinase Family (Ben M. Dunn).
   1.1 Introduction.
   1.2 Sequence Alignment and Family Tree.
   1.3 Three-Dimensional Structure.
   1.4 Conferences and Progress.
   1.5 Exploration of the Active Sites of Aspartic Proteinase and Relation to Drug Discovery.

   2.1 Introduction.
   2.2 Structures of Aspartic Proteases.
   2.3 Catalytic Mechanism and Substrate Specificity.
   2.4 Zymogen Activation.
   2.5 Inhibition and the Development of Inhibitor Drugs.
   2.6 Perspectives.
   2.7 Information Resource on Aspartic Proteases.

3. Human Aspartic Proteinases (John Kay and Daniel Bur).
   3.1 Introduction.
   3.2 Human Aspartic Proteinases.
   3.3 New Human Aspartic Proteinases.
   3.4 Concluding Remarks.

4. Structure-Based Drug Design Strategies for Inhibition of Aspartic Proteinases (Jon B. Cooper).
   4.1 Introduction.
   4.2 Associated Disease States.
   4.3 Development of Aspartic Proteinase Inhibitors.
   4.4 General Strategies for Design of Renin Inhibitors.
   4.5 Structural Studies of Renin Complexed with Inhibitors.
   4.6 Structure-Based Drug Design for the HIV Proteinase.
   4.7 Structure-Based Drug Design for Other Aspartic Proteinases.
   4.8 Possible New Leads from Macromolecular Inhibitor Complexes and Zymogen Structures.
Part Two. HIV-1 Protease as Target for the Treatment of HIV/AIDS.


5.1 Introduction.

5.2 HIV-1 and the AIDS Pandemic.

5.3 PR Interactions with Peptidic Inhibitors and Design of First Antiviral Inhibitors.

5.4 PR-Inhibitor Interactions Revealed in Atomic Resolution Structures.

5.5 The Challenge of Drug Resistance in HIV.

5.6 Future Perspectives.


6.1 Introduction.

6.2 Structure of HIV Protease.

6.3 Design of Inhibitors.

6.4 Viral Resistance to First-Generation Protease Inhibitors.

6.5 Perspectives.


7.1 Introduction.

7.2 Second-Generation Protease Inhibitors.

7.3 Conclusions.


8.1 Introduction.

8.2 Molecular Insights from Protein-Ligand X-Ray Crystal Structures of Early PIs and Design of Novel PIs Inspired by Nature.

8.3 Design of Novel Protease Inhibitors Containing Cyclic and Polycyclic Ether Templates.

8.4 Development of PIs Based Upon Our “Backbone Binding Concept” to Combat Drug-Resistant HIV.

8.5 Antiviral Activities, Resistance Profiles of TMC 126 (20), and Relevance to “Backbone Binding Concept”.

8.6 Selection of TMC114 and Its Subsequent Development to Darunavir.

8.7 High-Resolution X-Ray Structure of Darunavir-Bound HIV-1 Protease.

8.8 A Unique Dual Mode of Action: Darunavir also Inhibits Dimerization of HIV-1 Protease.

8.9 Optically Active Synthesis of Bis-THF Ligand for Initial Clinical Studies and Beyond.

8.10 Pharmacological Profile of Darunavir: ADME Properties.

8.11 Therapeutic Evaluation of DRV.

8.12 Conclusion.


9.1 Introduction.

9.2 Targeting the Viral Protease.

9.3 The Role of PIs and the Challenges Faced by HAART.

9.4 “Boosting”: A Critical Modification to the Clinical Efficacy of PIs.
9.5 HIV-1 Variants Resistant to Conventional PIs.
9.6 New Generation PIs with Activity against Drug-Resistant HIV-1.
9.7 A Novel Modality of HIV-1 Protease Inhibition: Dimerization Inhibition.
9.8 HIV-1 Resistance to Darunavir.
9.9 When to Start HAART with Protease Inhibitors.
9.10 Conclusions.

Part Three. Renin as Target for the Treatment of Hypertension.

10. Discovery and Development of Aliskiren, the First-in-Class Direct Renin Inhibitor for the Treatment of Hypertension (Jeanette M. Wood and Jürgen Maibaum).
10.1 Introduction.
10.2 The History of Renin and Aliskiren.
10.3 The Renin-Angiotensin-Aldosterone System.
10.4 History of the Renin Inhibitor Project in Ciba-Geigy/Novartis.
10.5 New Concept Toward (P_3-P_1) Topological Peptidomimetic Inhibitors.
10.6 Early Preclinical Leads.
10.7 Scalable Synthesis Development of Aliskiren.
10.8 Properties of Aliskiren.
10.9 Clinical Efficacy of Aliskiren.
10.10 Conclusions and Outlook.

11. Evolution of Diverse Classes of Renin Inhibitors Through the Years (Colin M. Tice and Suresh B. Singh).
11.1 Introduction.
11.2 Mechanism and Structural Biology of Renin.
11.3 Screening and Animal Models.
11.4 Peptidomimetic Renin Inhibitors.
11.5 Nonpeptidomimetic Renin Inhibitors.
11.6 Conclusions.

Part Four. γ-Secretase as Target for the Treatment of Alzheimer’s Disease.

12. γ-Secretase: A Unusual Enzyme with Many Possible Disease Targets, Including Alzheimer’s Disease (Johan Lundkvist and Urban Lendahl).
12.1 Introduction.
12.2 Presenilin: From a Zymogen to the Subunit of a Complex Enzyme.
12.3 γ-Secretase: A Promiscuous Enzyme That Mediates Regulated Intramembrane Proteolysis.
12.4 Structure of γ-Secretase.
12.5 Mechanism of γ-Secretase.
12.6 Pharmacology of γ-Secretase.
12.7 Concluding Remarks.

13. γ-Secretase Inhibition: An Overview of Development of Inhibitors for the Treatment of Alzheimer’s Disease (Christopher L. Hamblett, Sanjiv Shah, Richard Heidebrecht, Jr., and Benito Munoz).
13.1 Introduction.
13.2 APP Genetics.
13.3 Amyloid Cascade Hypothesis.
13.4 γ-Secretase Inhibitors: Compounds and Clinical Results.
13.5 Notch-Sparing γ-Secretase Inhibitors: Compounds and Clinical Results.
13.6 γ-Secretase Modulators: Compounds and Clinical Results.
13.7 Conclusion.

Part Five. β-Secretase as Target for the Treatment of Alzheimer’s Disease.

14.1 Introduction.
14.2 Cell Biology Evidence for β-Secretase.
14.3 BACE-Deficient Mice: Effect on Aß Production.
14.4 Other BACE Substrates.
14.5 BACE Structure and BACE Inhibitors.
14.6 Conclusions.

15.1 Introduction.
15.2 Discovery of Memapsin 2 and Its Identification as β-Secretase (by Jordan Tang).
15.3 Design of the First Substrate-Based Inhibitors: A Remarkable Scientific Adventure Between Two Laboratories (by Jordan Tang and Arun Ghosh).
15.4 Crystal Structure of Memapsin 2 and Binding of Inhibitors (by Lin Hong).
15.5 Evolution of Memapsin 2 Inhibitors (by Arun Ghosh).
15.6 Perspective.

16.1 Introduction.
16.2 Substrate-Based (Peptidic) Inhibitors.
16.3 Peptidomimetic Statine and Homostatine Inhibitors.
16.4 Hydroxyethylamine-Based Inhibitors.
16.5 Other Peptidomimetics.
16.6 Conclusions.

17. NonPeptide BACE1 Inhibitors: Design and Synthesis (Derek C. Cole and Matthew G. Bursavich).
17.1 Introduction.
17.2 Preliminary Peptidomemetic BACE1 Inhibitors.
17.3 Acyl Guanidine-Based Inhibitors.
17.4 Aminimidazolone-Based Inhibitors.
17.5 2-Aminopyridine and Pyrimidine-Based Inhibitors.
17.6 Aminimidazopyrimidine-Based Inhibitors.
17.7 2-Aminoquinazoline-Based Inhibitors.
17.8 Piperidine and Piperazine-Based Inhibitors.
17.9 Other Miscellaneous Scaffolds.
17.10 Conclusions.

Part Six. Plasmepsins and Other Aspartic Proteases as Drug Targets.

18. The Plasmepsins Family as Antimalarial Drug Targets (Adam J. Ruben, Yoshiaki Kiso and Ernesto Freire).

18.1 Introduction.
18.2 Plasmepsins In Vivo.
18.3 Plasmepsins In Vitro.
18.4 Plasmepsin Family Structures.
18.5 Plasmepsin Inhibitors.
18.6 Conclusions.

19. Plasmepsins Inhibitors as Potential Against Malaria: Starving the Parasite (Sandra Gemma).

19.1 Introduction.
19.2 The Plasmepsin Family of Enzymes.
19.3 Inhibitors of the Plasmepsin Family of Enzymes.
19.4 Transition-State Isostere-Based Inhibitors.
19.5 Nonpeptidic Inhibitors.
19.6 “Double-Drugs”
19.7 Conclusions.

20. Fungal Asparatic Proteases as Possible Therapeutic Targets (Michel Monod, Peter Staib, Utz Reichard, and Olivier Jousson).

20.1 Introduction.
20.2 Biochemical Properties of Fungal Proteases (Table 20.1).
20.3 Phylogeny of Fungal Aspartic Proteases.
20.4 Production of Fungal Aspartic Proteases.
20.5 Biological Functions of Aspartic Proteases in Fungi.
20.6 Secreted Aspartic Proteases in Virulence of C. albicans.
20.7 Functions of Aspartic Protease in C. albicans Virulence Processes.
20.8 Secreted Aspartic Proteases in the Virulence of Candida Species Other Than C. albicans.
20.9 Secreted Aspartic Proteases During Infection by Opportunistic Filamentous Fungi.
20.10 Fungal Aspartic Proteases as Possible Drug Targets.
20.11 Conclusions.

Index.